Scientists in the US are set to begin tests to see if a combination of two medications can benefit sufferers of Relapsing Remitting Multiple Sclerosis (MS).
Researchers from the Mount Sinai School of Medicine will investigate whether a combination of Avonex and Copaxone is better than single treatments with one of the two drugs.
The two substances are currently used during the early stages of relapsing forms of the disease but only provide a partial lowering of the risk of developing disability or suffering further attacks.
Study chairman Fred Lublin commented: "This is a very important trial because, if effective, combination therapy will allow us to take advantage of these agents that have different and complementary mechanisms of action to slow or halt progression of MS."
People taking part in the project will also be invited to participate in an additional study to investigate whether particular proteins and genes can help predict the progression of the disease.
Around 85,000 people in the UK have MS which, as yet, has no cure.